次世代ドラッグコンジュゲート市場：GalNacコンジュゲート、ペプチド薬物コンジュゲート、ペプチドオリゴヌクレオチドコンジュゲート、RNAiコンジュゲート、ペプチド受容体放射性核種療法、低分子-薬物コンジュゲート（SMDC）、およびその他のコンジュゲートに注目標的リガンドの種類（アミノ糖、脂質、ペプチド、低分子、ウイルス様粒子）、ペイロードの種類（ペプチド、ペプチド、低分子、オリゴヌクレオチド、放射性核種）、治療法の種類（単剤療法、併用療法）、投与経路（静脈内投与、皮下投与、その他）、作用機序（配列特異的標的結合、放射線誘発性細胞毒性、がん特異的表面標的媒介性細胞毒性、薬剤誘発性細胞毒性、受容体介在性細胞毒性、その他）および主要な適応症（消化器膵神経内分泌腫瘍、前立腺癌、乳癌脳転移による髄膜後葉癌腫症、遺伝性トランスサイレチンアミロイドーシス、動脈硬化性心血管病、重症高トリグリセリド血症、遺伝性血管性浮腫、急性肝ポルフィリン症、原発性高シュウ酸尿症、ヘテロ接合性家族性高コレステロール血症、血友病、低リスク骨髄異形成症候群、骨髄線維症、α1アンチトリプシン欠乏性肝疾患、家族性カイロミクロン血症症候群）、主要地域（北米、欧州、アジア太平洋地域、その他の地域）：産業動向と世界予測、2023-2035年

The Next Generation Drug Conjugates Market: Focus on GalNac Conjugate, Peptide Drug Conjugate, Peptide Oligonucleotide Conjugate, RNAi Conjugate, Peptide Receptor Radionuclide Therapy, Small Molecule-Drug Conjugate (SMDC), and Other Conjugates Distribution by Type of Targeting Ligand (Amino Sugar, Lipid, Peptide, Small Molecule and Virus-like Particles), Type of Payload (Peptide, Small Molecule, Oligonucleotide and Radionuclide), Type of Therapy (Monotherapy and Combination Therapy), Route of Administration (Intravenous, Subcutaneous and Others), Mechanism of Action (sequence-specific target binding, radiation induced cytotoxicity, cancer-specific surface target mediated cytotoxicity, drug induced cytotoxicity, receptor mediated internalization and cytotoxicity and others) and Key Target Indications (Gastroenteropancreatic Neuroendocrine Tumors, Prostate Cancer, Leptomeningeal Carcinomatosis caused by Breast Cancer Brain Metastases, Hereditary Transthyretin Amyloidosis, Atherosclerotic Cardiovascular Diseases, Severe Hypertriglyceridemia, Hereditary Angioedema, Acute Hepatic Porphyria, Primary Hyperoxaluria, Heterozygous Familial Hypercholesterolemia, Hemophilia, Low-Risk Myelodysplastic Syndrome, Myelofibrosis, Alpha-1 Antitrypsin Deficiency Liver Disease and Familial Chylomicronemia Syndrome) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2023-2035

次世代薬物複合体の世界市場規模は、2035年には154億7,000万米ドルに達すると予測され、予測期間2023-2035年の年平均成長率は18%と予測されている。次世代ドラッグコンジュゲートは、免疫反応の低減、臨床特... もっと見る

出版社	出版年月	電子版価格	ページ数	言語
Roots Analysis ルーツアナリシス	2023年9月1日	US$4,799 シングルユーザライセンスライセンス・価格情報注文方法はこちら	120	英語

サマリー

次世代薬物複合体の世界市場規模は、2035年には154億7,000万米ドルに達すると予測され、予測期間2023-2035年の年平均成長率は18%と予測されている。

次世代ドラッグコンジュゲートは、免疫反応の低減、臨床特性の改善、安定した構造、副作用の最小化、正確な治療デリバリー、細胞浸透性の強化、浸透性によって区別され、希少疾患、特に癌への取り組みに有望視されている。2020年、米国の希少疾患医療費は約1兆ドルに急増し、患者の平均医療費は60,248米ドルと、一般患者の2倍に達する。この医療費の高騰と希少疾患の世界的な重荷が相まって、関係者は代替手段を模索するようになり、先進的薬物複合体が希望に満ちた解決策として浮上してきた。
抗体薬物複合体（ADC）と同様に、ペプチド、アミノ糖、脂質、低分子など多様な非抗体標的薬剤を用いながら、優れた臨床的有効性と安定性を誇る。従来の薬剤の代わりに、オリゴヌクレオチド、アンチセンス・オリゴヌクレオチド、Si-RNA、薬剤、放射性核種などのペイロードを標的送達に利用する。このターゲティングリガンドとペイロードの融合は、ペプチド薬物コンジュゲート、ペプチド受容体放射性核種療法、GalNacコンジュゲート、Si-RNAコンジュゲートなど、さまざまなタイプの次世代薬物コンジュゲートを生み出し、固形がん、代謝異常、血液疾患などの疾患に対する有効性が証明されている。
USFDAは、6つの次世代薬物複合体（Lutathera®、Pluvicto®、Givlaari®、Oxlumo®、Leqvio®、Amvuttra®）を治療薬として認可した。これらの承認は、これらの先進的な治療法の臨床的勝利と、幅広い病状におけるその可能性を強調するものである。継続的な技術革新、有望な試験結果、迅速な承認、協力的な取り組みにより、次世代薬剤結合体市場は予測期間中に大きな成長が見込まれる。

レポート範囲
 次世代薬剤コンジュゲート市場の現状と短期・中期・長期的な展開に関するハイレベルな見解を提供する、調査中に得られた主要な洞察のエグゼクティブサマリー。
 次世代薬物コンジュゲートの一般的な概要、歴史的背景、構造、利点、およびGalNacコンジュゲート、ペプチド薬物コンジュゲートなどの様々な次世代薬物コンジュゲートの薬物動態学的特性に関する情報。
ペプチド放射性核種コンジュゲート、低分子薬物コンジュゲート、その他のコンジュゲート）、標的化リガンドの種類（アミノ糖、脂質、ペプチド、低分子、ウイルス様粒子）、ペイロードの種類、生物学的標的の種類、作用機序（配列特異的標的結合、放射線誘発細胞毒性、がん特異的表面標的媒介細胞毒性、薬物誘発細胞毒性、受容体を介した細胞内封入と細胞毒性、その他）、開発段階（前臨床、臨床、承認）、開発フェーズ（承認、第Ⅲ相、第Ⅱ相、第Ⅰ相、前臨床、探索）、治療タイプ（単剤治療、併用療法）、投与経路（静脈内、皮下、その他）、対象疾患適応（筋ジストロフィー、肺がん、肝炎、乳がん、非がん、非小細胞肺がん、非小細胞肺がん、非小細胞肺がん、非小細胞肺がん、非小細胞肺がん肝炎、乳がん、非アルコール性脂肪性肝炎、前立腺がん、卵巣がん、高血圧症、多毛症）、治療領域（心血管系疾患、遺伝性疾患、肝障害、代謝性疾患、筋骨格系疾患、がん性疾患、呼吸器系疾患、腎疾患、その他の疾患）、対象集団（小児、成人、高齢者）。さらに本章では、様々な次世代薬物複合体の開発企業について、その設立年、企業規模、本社所在地、最も活発なプレーヤー（医薬品候補の数）の情報を掲載しています。
 主要な次世代薬物複合体企業の詳細なプロフィール（承認・商業化済み、または開発フェーズIIIにあるパイプライン中の医薬品候補の数に基づいてリストアップ）と、それぞれの製品ポートフォリオ。各プロフィールには、企業概要、製品ポートフォリオ、承認済みまたは臨床開発第III相段階にある医薬品候補の概要、最近の開発状況、開発企業の将来展望が掲載されています。
 臨床試験登録年、臨床試験フェーズ、登録患者数、スポンサー／共同研究者のタイプ、年齢層、最も活発な業界プレーヤー、主要な医薬品候補、主要目的、治療領域、主要地域など、いくつかの関連パラメータに基づく、様々な次世代薬物複合体の完了済み、進行中、および計画中の臨床試験の詳細な分析。
 2018年以降に様々な利害関係者間で締結されたパートナーシップの詳細な分析であり、製品開発・商業化契約、研究開発契約、サービス契約、プラットフォーム／技術ライセンス契約、買収、臨床試験契約、製品ライセンス契約、合弁事業などを網羅している。
 2018年以降、次世代薬物複合体に関連する研究の実施に従事する研究機関に授与された助成金を、助成金授与年、授与額、資金提供機関センター、支援期間、助成金申請の種類、助成金授与の目的、活動コード、関与する研究セクション、人気のあるNIH部門（助成金授与数に基づく）、著名なプログラム担当者、主要な受領組織、主要地域などの様々な重要なパラメータに基づいて分析。
 2018年以降に発表された次世代薬物コンジュゲートに焦点を当てた400以上の査読付き科学論文を、発表年、発表の種類、発表数、コンジュゲートの種類、標的適応症、著作権者に基づいて詳細に分析。本章では、主要な出版社と主要ジャーナル（掲載論文数とインパクトファクターの観点から）も紹介している。
 治験中止の状況、治験中止の段階、平均治験年、治療法の種類、標的適応症、薬剤失敗の理由など、様々な関連パラメータに基づき、臨床開発の後期に進めなかった次世代薬剤コンジュゲートを包括的に分析。
 最近承認され商品化された次世代薬剤結合体について、投与頻度、薬剤の有効性、薬剤の独占性、薬剤の指定、致死率、地理的範囲、クラス内競争、治療ライン、普及率、価格、治療の種類、開発者間の既存の競争など、いくつかの関連パラメータに基づく洞察に満ちた成功プロトコル分析。
 2035年までの次世代薬物複合体市場の成長可能性を強調する詳細な市場予測分析。将来機会の詳細を提供するため、予測はコンジュゲートのタイプ（ペプチド受容体放射性核種治療、リガンド媒介RNAiコンジュゲート、リガンドコンジュゲート抗センス薬、ペプチド薬物コンジュゲート）、主要な標的適応症（消化器膵神経内分泌腫瘍、前立腺がん、乳がん脳転移によるレプト髄膜がん腫症、遺伝性トランスサイレチンアミロイドーシス、アテローム性動脈硬化性心血管系疾患、重症高トリグリセリド血症、遺伝性血管性浮腫、急性肝ポルフィリン症、原発性高オキサ尿症、ヘテロ接合性家族性高コレステロール血症、血友病、低リスク骨髄異形成症候群、骨髄線維症、α-1抗トリプシン欠乏性肝疾患、家族性カイロミクロン血症症候群）、主要地域（北米、欧州、アジア太平洋地域、その他の地域）。
主要市場企業
 アドバンスト・アクセラレーター・アプリケーションズ
 アルナイラム・ファーマシューティカルズ
 アローヘッド製薬
 ディセルナ・ファーマシューティカルズ
 ジェロン・コーポレーション
 イオニス・ファーマシューティカルズ

ページTOPに戻る

1. PREFACE
1.1. Next Generation Drug Conjugates Market Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Overview of Next Generation Drug Conjugates
3.2. Key Historical Events
3.3. Structure of Next Generation Drug Conjugates
3.4. Biochemical Interaction and Mechanism of Action
3.5. Key Target Indications
3.6. Advantages of Next Generation Drug Conjugates
3.7 Challenges associated with Next Generation Drug Conjugates
3.8. Future Perspectives
4. MARKET LANDSCAPE
4.1. Methodology
4.2. Next Generation Drug Conjugates: List of Therapies
4.2.1. Analysis by Type of Conjugate
4.2.2. Analysis by Type of Targeting Ligand
4.2.3. Analysis by Type of Payload
4.2.4. Analysis by Biological Target
4.2.5. Analysis by Mechanism of Action
4.2.6. Analysis by Stage of Development
4.2.7. Analysis by Phase of Development
4.2.8. Analysis by Type of Therapy
4.2.9. Analysis by Route of Administration
4.2.10. Analysis by Target Disease Indication
4.2.11. Analysis by Therapeutic Area
4.2.12. Analysis by Target Population
4.2.13. Analysis by Type of Conjugate and Stage of Development
4.2.14. Analysis by Type of Conjugate and Target Populatio
4.3 Next Generation Drug Conjugates: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters (Region-wise)
4.3.4. Analysis by Location of Headquarters (Country-wise)
4.3.5. Analysis by Year of Establishment, Company Size and Location of Headquarters (Region-wise)
4.3.6. Most Active Players: Analysis by Number of Drug Candidates
5. COMPANY AND DRUG PROFILES
5.1. Advanced Accelerator Applications
5.1.1. Company Overview
5.1.2. Management Team
5.1.3. Product Portfolio
5.1.3.1. Lutathera®
5.1.3.1.1 Drug Overview
5.1.3.1.2. Clinical Trial Information
5.1.3.1.3. Clinical Trial Results
5.1.3.1.4. Dosing Regimen
5.1.3.1.5. Estimated Sales
5.1.3.2. Pluvicto®
5.1.3.2.1 Drug Overview
5.1.3.2.2. Clinical Trial Information
5.1.3.2.3. Clinical Trial Results
5.1.3.2.4. Dosing Regimen
5.1.3.2.5. Estimated Sales
5.1.4. Recent Developments and Future Outlook
5.2. Alnylam Pharmaceuticals
5.2.1. Company Overview
5.2.2. Management Team
5.2.3. Product Portfolio
5.2.3.1. Givlaari®
5.2.3.1.1. Drug Overview
5.2.3.1.2. Clinical Trial Information
5.2.3.1.3. Clinical Trial Results
5.2.4.1.4. Dosing Regimen
5.2.3.2. Oxlumo®
5.2.3.2.1. Drug Overview
5.2.3.2.2. Clinical Trial Information
5.2.3.2.3. Clinical Trial Results
5.2.3.2.4. Dosing Regimen
5.2.3.3. Leqvio®
5.2.3.3.1. Drug Overview
5.2.3.3.2. Clinical Trial Information
5.2.3.3.3. Clinical Trial Results
5.2.3.3.4. Dosing Regimen
5.2.3.4. Amvuttra®
5.2.3.4.1. Drug Overview
5.2.3.4.2. Clinical Trial Information
5.2.3.4.3. Clinical Trial Results
5.2.3.4.4. Dosing Regimen
5.2.4. Recent Developments and Future Outlook
5.3. Arrowhead Pharmaceuticals
5.3.1. Company Overview
5.3.2. Management Team
5.3.3. Product Portfolio
5.3.3.1. Olpasiran
5.3.3.1.1. Drug Overview
5.3.3.1.2. Clinical Trial Information
5.3.3.1.3. Clinical Trial Results
5.3.3.1.4. Dosing Regimen
5.3.3.2. ARO-AAT
5.3.3.2.1. Drug Overview
5.3.3.2.2. Clinical Trial Information
5.3.3.2.3. Clinical Trial Results
5.3.3.2.4. Dosing Regimen
5.3.3.3. ARO-APOC3
5.3.3.3.1. Drug Overview
5.3.3.3.2. Clinical Trial Information
5.3.3.3.3. Clinical Trial Results
5.3.3.3.4. Dosing Regimen
5.3.4. Recent Developments and Future Outlook
5.4. Dicerna Pharmaceuticals
5.4.1. Company Overview
5.4.2. Management Team
5.4.3. Product Portfolio
5.4.3.1. Nedosiran
5.4.3.1.1 Drug Overview
5.4.3.1.2. Clinical Trial Information
5.4.3.1.3. Clinical Trial Results
5.4.3.1.4. Dosing Regimen
5.4.4. Recent Developments and Future Outlook
5.5. Geron
5.5.1. Company Overview
5.5.2. Management Team
5.5.3. Product Portfolio
5.5.3.1. Imtelstat
5.5.3.1.1. Drug Overview
5.5.3.1.2. Clinical Trial Information
5.5.3.1.3. Clinical Trial Results
5.5.3.1.4. Dosing Regimen
5.5.4. Recent Developments and Future Outlook
5.6. Ionis Pharmaceuticals
5.6.1. Company Overview
5.6.2. Management Team
5.6.3. Product Portfolio
5.6.3.1. Eplontersen
5.6.3.1.1 Drug Overview
5.6.3.1.2. Clinical Trial Information
5.6.3.1.3. Clinical Trial Results
5.6.3.1.4. Dosing Regimen
5.6.3.2. Olezarsen
5.6.3.2.1. Drug Overview
5.6.3.2.2. Clinical Trial Information
5.6.3.2.3. Clinical Trial Results
5.6.3.2.4. Dosing Regimen
5.6.3.3. Pelacarsen
5.6.3.3.1. Drug Overview
5.6.3.3.2. Clinical Trial Information
5.6.3.3.3. Clinical Trial Results
5.6.3.3.4. Dosing Regimen
5.6.3.3.5. Estimated Sales
5.6.3.4. Donidalorsen
5.6.3.4.1 Drug Overview
5.6.3.4.2. Clinical Trial Information
5.6.3.4.3. Clinical Trial Results
5.6.3.4.4. Dosing Regimen
5.6.4. Recent Developments and Future Outlook
6. CLINICAL TRIAL ANALYSIS
6.1. Analysis Methodology and Key Parameters
6.2. Next Generation Drug Conjugates: Clinical Trial Analysis
6.2.1. Analysis by Trial Registration Year
6.2.2. Analysis by Trial Phase
6.2.3. Analysis by Trial Status
6.2.4. Analysis by Therapeutic Area
6.2.5. Analysis by Primary Purpose
6.2.6. Analysis by Age Group
6.2.7. Analysis by Type of Sponsor
6.2.8. Most Active Industry Players: Analysis by Number of Trials
6.2.9. Leading Drug Candidates: Analysis by Number of Trials
6.2.10. Analysis by Trial Registration Year and Trial Location
6.2.11. Analysis by Trial Registration Year and Enrolled Patient Population
6.2.12. Analysis by Trial Phase and Enrolled Patient Population
6.2.13. Analysis by Trial Status and Enrolled Patient Population
6.2.14. Analysis by Trial Location and Enrolled Patient Population
6.2.15. Analysis by Trial Status and Trial Location
7. PARTNERSHIPS AND COLLABORATIONS
7.1. Partnership Models
7.2. Next Generation Drug Conjugates: Partnerships and Collaborations
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Year and Type of Partnership
7.3.4. Analysis by Type of Partner
7.3.5. Analysis by Year of Partnership and Type of Partner
7.3.6. Analysis by Type of Partnership and Type of Partner
7.3.7. Analysis by Type of Partner and Parent Company Size
7.3.8. Analysis by Therapeutic Area
7.3.9. Most Active Players: Analysis by Number of Partnerships
7.3.10. Analysis by Geography
7.3.10.1. Analysis by Type of Geography (Region-wise)
7.3.10.2. Analysis by Type of Geography (Country-wise)
7.3.10.3. Intercontinental and Intracontinental Agreements
8. ACADEMIC GRANTS ANALYSIS
8.1. Methodology and Key Parameters
8.2. Next Generation Drug Conjugates: Academic Grants Analysis
8.2.1. Analysis by Year of Grant Award
8.2.2. Analysis by Amount Awarded
8.2.3. Analysis by Funding Institute Center
8.2.4. Analysis by Support Period
8.2.5. Analysis by Funding Institute Center and Support Period
8.2.6. Analysis by Type of Grant Application
8.2.7. Analysis by Purpose of Grant
8.2.8. Analysis by Activity Code
8.2.9. Analysis by Study Section
8.2.10. Popular NIH Departments: Analysis by Number of Grants
8.2.11. Analysis by Type of Recipient Organization
8.2.11.1. Popular Recipient Organizations: Analysis by Number of Grants
8.2.11.2. Popular Recipient Organizations: Analysis by Amount Awarded
8.2.12. Prominent Program Officers: Analysis by Number of Grants
8.2.13 Analysis by Location of Recipient Organizations
9. PUBLICATION ANALYSIS
9.1. Analysis Methodology and Key Parameters
9.2. Next Generation Drug Conjugates: Publication Analysis
9.2.1. Analysis by Year of Publication
9.2.2. Analysis by Type of Publication
9.2.3. Analysis by Type of Conjugate
9.2.4. Analysis by Target Indication
9.2.5. Analysis by Copyright Holder
9.2.6. Word Cloud: Emerging Focus Area
9.2.7. Most Active Publishers: Analysis by Number of Publications
9.2.8. Key Journals: Analysis by Number of Publications
9.2.9. Key Journals: Analysis by Impact Factor
10. DRUG FAILURE ANALYSIS
10.1. Analysis Methodology and Key Parameters
10.2. Next Generation Drug Conjugates: Drug Failure Analysis
10.2.1. Analysis by Status of Discontinuation
10.2.2. Analysis by Phase of Discontinuation
10.2.3. Analysis by Average Trial Year
10.2.4. Analysis by Type of Therapy
10.2.5. Analysis by Target Indication
10.2.6. Analysis by Reason for Drug Failure
11. SUCCESS PROTOCOL ANALYSIS
11.1. Methodology and Key Parameters
11.2. Key Assumptions and Scoring Criteria
11.3. Success Protocol Analysis
11.4. Assessment of Approved Next Generation Drug Conjugates: Harvey Ball Analysis
12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
12.1. Key Assumptions and Forecast Methodology
12.2. Next Generation Drug Conjugates Market, 2023-2035
12.2.1. Next Generation Drug Conjugates Market: Distribution by Type of Conjugate, 2023 and 2035
12.2.1.1. Next Generation Drug Conjugates Market for Peptide Radionuclide Conjugates, 2023-2035
12.2.1.2. Next Generation Drug Conjugates Market for Ligand Conjugated Anti Sense Medicine, 2023-2035
12.2.1.3. Next Generation Drug Conjugates Market for Ligand Mediated RNAi Conjugates, 2023-2035
12.2.1.4. Next Generation Drug Conjugates Market for Peptide Drug Conjugates, 2023-2035
12.2.2. Next Generation Drug Conjugates Market: Distribution by Targeting Ligand
12.2.2.1 Next Generation Drug Conjugates Market for Amino Sugars, 2023-2035
12.2.2.2 Next Generation Drug Conjugates Market for Peptides, 2023-2035
12.2.2.3 Next Generation Drug Conjugates Market for Lipids, 2023-2035
12.2.3. Next Generation Drug Conjugates Market: Distribution by Payload
12.2.3.1. Next Generation Drug Conjugates Market for Radionuclides, 2023-2035
12.2.3.2. Next Generation Drug Conjugates Market for Drugs, 2023-2035
12.2.3.3. Next Generation Drug Conjugates Market for Antisense Oligonucleotides, 2023-2035
12.2.3.4 Next Generation Drug Conjugates Market for si-RNAs, 2023-2035
12.2.4. Next Generation Drug Conjugates Market: Distribution by Therapy
12.2.4.1. Next Generation Drug Conjugates Market for Monotherapy, 2023-2035
12.2.4.2. Next Generation Drug Conjugates Market for Combination Therapy, 2023-2035
12.2.5. Next Generation Drug Conjugates Market: Distribution by Route of Administration
12.2.5.1. Next Generation Intravenous Drug Conjugates Market, 2023-2035
12.2.5.2. Next Generation Subcutaneous Drug Conjugates Market, 2023-2035
12.2.6. Next Generation Drug Conjugates Market: Distribution by Target Disease Indication, 2023 and 2035
12.2.6.1. Next Generation Drug Conjugates Market for Gastroenteropancreatic Neuroendocrine Tumors, 2023-2035
12.2.6.2. Next Generation Drug Conjugates Market for Prostate Cancer, 2023-2035
12.2.6.3. Next Generation Drug Conjugates Market for Leptomeningeal Carcinomatosis caused by Breast Cancer Brain Metastases, 2023-2035
12.2.6.4. Next Generation Drug Conjugates Market for Hereditary Transthyretin Amyloidosis, 2023-2035
12.2.6.5. Next Generation Drug Conjugates Market for Atherosclerotic Cardiovascular Diseases, 2023-2035
12.2.6.6. Next Generation Drug Conjugates Market for Severe Hypertriglyceridemia, 2023-2035
12.2.6.7. Next Generation Drug Conjugates Market for Hereditary Angioedema, 2023-2035
12.2.6.8. Next Generation Drug Conjugates Market for Acute Hepatic Porphyria, 2023-2035
12.2.5.9. Next Generation Drug Conjugates Market for Primary Hyperoxaluria, 2023-2035
12.2.5.10. Next Generation Drug Conjugates Market for Heterozygous Familial Hypercholesterolemia, 2023-2035
12.2.5.11. Next Generation Drug Conjugates Market for Hemophilia, 2023-2035
12.2.5.12. Next Generation Drug Conjugates Market for Low-Risk Myelodysplastic Syndrome, 2023-2035
12.2.5.13. Next Generation Drug Conjugates Market for Myelofibrosis, 2023-2035
12.2.5.14. Next Generation Drug Conjugates Market for Alpha-1 Antitrypsin Deficiency Liver Disease, 2023-2035
12.2.5.15. Next Generation Drug Conjugates Market for Familial Chylomicronemia Syndrome, 2023-2035
12.2.6. Next Generation Drug Conjugates Market: Distribution by Key Geographical Regions, 2023 and 2035
12.2.6.1. Next Generation Drug Conjugates Market in North America, 2023-2035
12.2.6.1.1. Next Generation Drug Conjugates Market in the US, 2022-2035
12.2.6.1.2. Next Generation Drug Conjugates Market in Canada, 2022-2035
12.2.6.2. Next Generation Drug Conjugates Market in Europe, 2023-2035
12.2.6.2.1. Next Generation Drug Conjugates Market in the UK, 2022-2035
12.2.6.2.2. Next Generation Drug Conjugates Market in France, 2022-2035
12.2.6.2.3. Next Generation Drug Conjugates Market in Germany, 2022-2035
12.2.6.2.4. Next Generation Drug Conjugates Market in Spain, 2022-2035
12.2.6.2.5. Next Generation Drug Conjugates Market in Italy, 2022-2035
12.2.6.2.6. Next Generation Drug Conjugates Market in Rest of the Europe, 2022-2035
12.2.6.3. Next Generation Drug Conjugates Market in Asia-Pacific and Rest of the World, 2023-2035
12.2.6.3.1. Next Generation Drug Conjugates Market in Japan, 2023-2035
12.2.6.3.2. Next Generation Drug Conjugates Market in Australia, 2023-2035
12.2.6.3.3. Next Generation Drug Conjugates Market in Brazil, 2023-2035
12.3. Next Generation Drug Conjugates Market: Product-wise Sales Forecast, 2023-2035
12.3.1. Lutathera®
12.3.1.1. Sales Forecast (USD Million)
12.3.1.2. Net Present Value (USD Million)
12.3.1.3. Value Creation Analysis
12.3.2. Pluvicto®
12.3.2.1. Sales Forecast (USD Million)
12.3.2.2. Net Present Value (USD Million)
12.3.2.3. Value Creation Analysis
12.3.3. Givlaari®
12.3.3.1. Sales Forecast (USD Million)
12.3.3.2. Net Present Value (USD Million)
12.3.3.3. Value Creation Analysis
12.3.4. Oxlumo®
12.3.4.1. Sales Forecast (USD Million)
12.3.4.2. Net Present Value (USD Million)
12.3.4.3. Value Creation Analysis
12.3.5. Leqvio®
12.3.5.1. Sales Forecast (USD Million)
12.3.5.2. Net Present Value (USD Million)
12.3.5.3. Value Creation Analysis
12.3.6. Amvuttra®
12.3.6.1. Sales Forecast (USD Million)
12.3.6.2. Net Present Value (USD Million)
12.3.6.3. Value Creation Analysis
12.3.7. Eplontersen
12.3.7.1. Sales Forecast (USD Million)
12.3.7.2. Net Present Value (USD Million)
12.3.7.3. Value Creation Analysis
12.3.8. Olezarsen
12.3.8.1. Sales Forecast (USD Million)
12.3.8.2. Net Present Value (USD Million)
12.3.8.3. Value Creation Analysis
12.3.9. Pelacarsen
12.3.9.1. Sales Forecast (USD Million)
12.3.9.2. Net Present Value (USD Million)
12.3.9.3. Value Creation Analysis
12.3.10. Donidalorsen
12.3.10.1. Sales Forecast (USD Million)
12.3.10.2. Net Present Value (USD Million)
12.3.10.3. Value Creation Analysis
12.3.11. Fitusiran
12.3.11.1. Sales Forecast (USD Million)
12.3.11.2. Net Present Value (USD Million)
12.3.11.3. Value Creation Analysis
12.3.12. Nedosiran
12.3.12.1. Sales Forecast (USD Million)
12.3.12.2. Net Present Value (USD Million)
12.3.12.3. Value Creation Analysis
12.3.13. Imetlestat
12.3.13.1. Sales Forecast (USD Million)
12.3.13.2. Net Present Value (USD Million)
12.3.13.3. Value Creation Analysis
12.3.14. Olpasiran
12.3.14.1. Sales Forecast (USD Million)
12.3.14.2. Net Present Value (USD Million)
12.3.14.3. Value Creation Analysis
12.3.15. ARO-AAT
12.3.15.1. Sales Forecast (USD Million)
12.3.15.2. Net Present Value (USD Million)
12.3.15.3. Value Creation Analysis
12.3.16. ARO-APOC3
12.3.16.1. Sales Forecast (USD Million)
12.3.16.2. Net Present Value (USD Million)
12.3.16.3. Value Creation Analysis
12.3.17. ANG-1005
12.3.17.1. Sales Forecast (USD Million)
12.3.17.2. Net Present Value (USD Million)
12.3.17.3. Value Creation Analysis
13. APPENDIX 1: TABULATED DATA
14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

ページTOPに戻る

Table of Contents

Summary

The global next generation drug conjugate market is anticipated to be valued at USD 15.47 billion in 2035 anticipated to grow at a CAGR of 18% during the forecast period 2023-2035.

The next generation drug conjugates, distinguished by reduced immune reactions, improved clinical traits, stable structures, minimized side effects, precise treatment delivery, enhanced cell penetration, and permeability, shows promise in tackling rare diseases, particularly cancers. In 2020, US rare disease medical expenses surged to nearly USD 1 trillion, with patients spending an average of USD 60,248—twice the amount for general patients. This escalating healthcare cost, coupled with the global burden of rare diseases, has prompted stakeholders to explore alternatives, and these advanced drug conjugates emerge as a hopeful solution.
Similar to antibody drug conjugates (ADCs), these advanced versions boast superior clinical efficacy and stability while employing diverse non-antibody targeting agents such as peptides, amino sugars, lipids, and small molecules. Instead of traditional drugs, they utilize payloads like oligonucleotides, antisense oligonucleotides, si-RNA, drugs, and radionuclides for targeted delivery. This fusion of targeting ligands and payloads has spawned various types of next generation drug conjugates, including peptide drug conjugates, peptide receptor radionuclide therapy, GalNac conjugates, si-RNA conjugates, all proving effective against diseases like solid tumors, metabolic disorders, and hematological disorders.
The USFDA has greenlit six next generation drug conjugates for therapeutic use—Lutathera®, Pluvicto®, Givlaari®, Oxlumo®, Leqvio®, and Amvuttra®. These approvals underscore the clinical triumphs of these advanced therapies and their potential across a wide range of medical conditions. With ongoing innovation, promising trial outcomes, expedited approvals, and collaborative efforts, the market for next generation drug conjugates anticipates significant growth in the forecast period.

Report Coverage
 An executive summary of the key insights captured during our research, offering a high-level view on the current state of the next generation drug conjugates market and its likely evolution in the short to mid and long term.
 A general overview of the next generation drug conjugates, highlighting their historical background, as well as information on their structure, advantages, and the pharmacokinetic properties of the various next generation drug conjugates, such as GalNac conjugates, peptide drug conjugates and others.
 Information on more than 200 next generation drug conjugates / next generation targeted therapeutics that are either approved or being evaluated in different stages of development (clinical or pre-clinical), based on several relevant parameters, such as type of conjugate (GalNac conjugate, peptide drug conjugate, peptide oligonucleotide conjugate, RNAi conjugate, peptide radionuclide conjugate, small molecule drug conjugate, and other conjugates), type of targeting ligand (amino sugar, lipid, peptide, small molecule and virus-like particles), type of payload, type of biological target, mechanism of action (sequence-specific target binding, radiation induced cytotoxicity, cancer-specific surface target mediated cytotoxicity, drug induced cytotoxicity, receptor mediated internalization and cytotoxicity and others), stage of development (preclinical, clinical and approved), phase of development (approved, phase III, phase II, phase I, preclinical and discovery), type of therapy (monotherapy and combination therapy), route of administration (intravenous, subcutaneous and others), target disease indication (muscular dystrophy, lung cancer, hepatitis, breast cancer, nonalcoholic steatohepatitis, prostate cancer, ovarian cancer, hypertension and hypertriglycedermia), therapeutic area (cardiovascular disorders, genetic disorders, hepatic disorders, metabolic disorders, musculoskeletal disorders, oncological disorders, respiratory disorders, renal disorders, and other disorders) and target population (children, adults and older adults). In addition, the chapter features information on various next generation drug conjugate developers, based on their year of establishment, company size, location of headquarters and most active players (in terms of number of drug candidates).
 Elaborated profiles of leading next generation drug conjugate companies (shortlisted based on number of drug candidates in pipeline that have been approved / commercialized or in Phase III of development) and their respective product portfolios. Each profile features a brief overview of the company, product portfolio, an overview of the drug candidates which are either approved or are in phase III stage of clinical development, along with recent developments, and an informed future outlook of the developer.
 An in-depth analysis of completed, ongoing, and planned clinical studies of various next generation drug conjugates, based on several relevant parameters, such as trial registration year, trial phase, enrolled patient population, type of sponsor / collaborator, age group, most active industry players, leading drug candidate, primary purpose, therapeutic area and key geographical regions.
 An in-depth analysis of partnerships that have been inked between various stakeholders since 2018, covering product development and commercialization agreement, research and development agreement, service agreement, platform / technology licensing agreement, acquisition, clinical trial agreement, product licensing agreement, joint ventures and others.
 Grants that have been awarded to research institutes engaged in conducting research related to next generation drug conjugates, since 2018, based on various important parameters, such as year of grant award, amount awarded, funding institute center, support period, type of grant application, purpose of grant award, activity code, study section involved, popular NIH departments (based on number of grants awarded), prominent program officers, leading recipient organizations and key regions.
 An in-depth analysis of more than 400 peer-reviewed, scientific articles focused on next generation drug conjugates that have been published since 2018, based on year of publication, type of publication, number of publications, type of conjugate, target indication and copyright holders. The chapter also highlights the leading publishers and key journals (in terms of number of articles published and impact factor).
 A comprehensive analysis of the next generation drug conjugates that failed to progress to later stages of clinical development, based on various relevant parameters, such as trial status of discontinuation, trial phase of discontinuation, average trial year, type of therapy, target indication and reason for drug failure.
 Insightful success protocol analysis of recently approved and commercialized next generation drug conjugates, based on several relevant parameters, such as dosing frequency, drug efficacy, drug exclusivity, drug designation, fatality rate, geographical reach, intra-class competition, line of treatment, prevalence, price, type of therapy, and existing competition among developers.
 An elaborate market forecast analysis, highlighting the likely growth of the next generation drug conjugates market, till the year 2035. In order to provide details on future opportunity, our projections have been segmented on the basis of type of conjugate (peptide receptor radionuclide therapy, ligand mediated RNAi conjugates, ligand conjugates anti sense medicine and peptide drug conjugates), key target indications (gastroenteropancreatic neuroendocrine tumors, prostate cancer, leptomeningeal carcinomatosis caused by breast cancer brain metastases, hereditary transthyretin amyloidosis, atherosclerotic cardiovascular diseases, severe hypertriglyceridemia, hereditary angioedema, acute hepatic porphyria, primary hyperoxaluria, heterozygous familial hypercholesterolemia, hemophilia, low-risk myelodysplastic syndrome, myelofibrosis, alpha-1 antitrypsin deficiency liver disease and familial chylomicronemia syndrome), and key geographical regions (North America, Europe, Asia-Pacific, and Rest of the World).
Key Market Companies
 Advanced Accelerator Applications
 Alnylam Pharmaceuticals
 Arrowhead Pharmaceuticals
 Dicerna Pharmaceuticals
 Geron Corporation
 Ionis Pharmaceuticals

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野の最新刊レポート

本レポートと同分野の最新刊レポートはありません。

Roots Analysis社の分野での最新刊レポート

最新刊レポートはありません。

本レポートと同じKEY WORD（）の最新刊レポート

本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問

Roots Analysis社はどのような調査会社ですか?

Roots Analysisは2013年設立の医薬品・医療機器が専門の調査会社です。医薬品の製造委託や創薬のデジタル化など、最新の医薬業界の分析を行っています。もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野の最新刊レポート

Roots Analysis社の分野での最新刊レポート

本レポートと同じKEY WORD（）の最新刊レポート

よくあるご質問

Roots Analysis社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?